|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PDHX |
Gene summary for PDHX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PDHX | Gene ID | 8050 |
| Gene name | pyruvate dehydrogenase complex component X | |
| Gene Alias | DLDBP | |
| Cytomap | 11p13 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | O00330 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8050 | PDHX | LZE4T | Human | Esophagus | ESCC | 5.91e-10 | 3.97e-01 | 0.0811 |
| 8050 | PDHX | LZE7T | Human | Esophagus | ESCC | 2.31e-09 | 4.62e-01 | 0.0667 |
| 8050 | PDHX | LZE22T | Human | Esophagus | ESCC | 5.55e-03 | 3.13e-01 | 0.068 |
| 8050 | PDHX | LZE24T | Human | Esophagus | ESCC | 2.65e-14 | 3.54e-01 | 0.0596 |
| 8050 | PDHX | P1T-E | Human | Esophagus | ESCC | 7.55e-03 | 2.63e-01 | 0.0875 |
| 8050 | PDHX | P2T-E | Human | Esophagus | ESCC | 5.66e-23 | 2.52e-01 | 0.1177 |
| 8050 | PDHX | P4T-E | Human | Esophagus | ESCC | 1.21e-06 | 2.44e-01 | 0.1323 |
| 8050 | PDHX | P5T-E | Human | Esophagus | ESCC | 1.79e-08 | 2.18e-02 | 0.1327 |
| 8050 | PDHX | P8T-E | Human | Esophagus | ESCC | 3.71e-26 | 3.25e-01 | 0.0889 |
| 8050 | PDHX | P9T-E | Human | Esophagus | ESCC | 8.25e-12 | 2.25e-01 | 0.1131 |
| 8050 | PDHX | P10T-E | Human | Esophagus | ESCC | 6.63e-20 | 1.82e-01 | 0.116 |
| 8050 | PDHX | P11T-E | Human | Esophagus | ESCC | 4.24e-04 | 3.76e-01 | 0.1426 |
| 8050 | PDHX | P12T-E | Human | Esophagus | ESCC | 2.20e-22 | 3.04e-01 | 0.1122 |
| 8050 | PDHX | P15T-E | Human | Esophagus | ESCC | 3.72e-18 | 3.70e-01 | 0.1149 |
| 8050 | PDHX | P16T-E | Human | Esophagus | ESCC | 3.35e-21 | 2.26e-01 | 0.1153 |
| 8050 | PDHX | P20T-E | Human | Esophagus | ESCC | 1.15e-09 | 2.45e-01 | 0.1124 |
| 8050 | PDHX | P21T-E | Human | Esophagus | ESCC | 3.85e-11 | 2.11e-01 | 0.1617 |
| 8050 | PDHX | P22T-E | Human | Esophagus | ESCC | 3.04e-38 | 6.36e-01 | 0.1236 |
| 8050 | PDHX | P23T-E | Human | Esophagus | ESCC | 5.88e-06 | 1.68e-01 | 0.108 |
| 8050 | PDHX | P24T-E | Human | Esophagus | ESCC | 4.44e-19 | 1.89e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| GO:0009150111 | Esophagus | ESCC | purine ribonucleotide metabolic process | 213/8552 | 368/18723 | 1.40e-06 | 1.69e-05 | 213 |
| GO:0046390110 | Esophagus | ESCC | ribose phosphate biosynthetic process | 119/8552 | 190/18723 | 1.73e-06 | 2.06e-05 | 119 |
| GO:00442725 | Esophagus | ESCC | sulfur compound biosynthetic process | 96/8552 | 148/18723 | 1.86e-06 | 2.16e-05 | 96 |
| GO:0006163111 | Esophagus | ESCC | purine nucleotide metabolic process | 226/8552 | 396/18723 | 2.81e-06 | 3.21e-05 | 226 |
| GO:000916516 | Esophagus | ESCC | nucleotide biosynthetic process | 150/8552 | 254/18723 | 1.12e-05 | 1.06e-04 | 150 |
| GO:0009260110 | Esophagus | ESCC | ribonucleotide biosynthetic process | 112/8552 | 182/18723 | 1.12e-05 | 1.06e-04 | 112 |
| GO:190129316 | Esophagus | ESCC | nucleoside phosphate biosynthetic process | 151/8552 | 256/18723 | 1.15e-05 | 1.08e-04 | 151 |
| GO:00338664 | Esophagus | ESCC | nucleoside bisphosphate biosynthetic process | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:00340304 | Esophagus | ESCC | ribonucleoside bisphosphate biosynthetic process | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:00340334 | Esophagus | ESCC | purine nucleoside bisphosphate biosynthetic process | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:007252217 | Esophagus | ESCC | purine-containing compound biosynthetic process | 120/8552 | 200/18723 | 3.02e-05 | 2.51e-04 | 120 |
| GO:0009152110 | Esophagus | ESCC | purine ribonucleotide biosynthetic process | 103/8552 | 169/18723 | 4.40e-05 | 3.51e-04 | 103 |
| GO:000616417 | Esophagus | ESCC | purine nucleotide biosynthetic process | 113/8552 | 191/18723 | 1.16e-04 | 8.04e-04 | 113 |
| GO:00353844 | Esophagus | ESCC | thioester biosynthetic process | 32/8552 | 45/18723 | 4.87e-04 | 2.70e-03 | 32 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PDHX | SNV | Missense_Mutation | novel | c.1328N>A | p.Gly443Glu | p.G443E | O00330 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A1NE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| PDHX | insertion | Nonsense_Mutation | novel | c.757_758insGCTAAATATGTAATATTAGCATAACTAATATTAGCTATTAGCATAA | p.Pro253ArgfsTer2 | p.P253Rfs*2 | O00330 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PDHX | insertion | Nonsense_Mutation | novel | c.1396_1397insAAACTAAAAAACACTAGATTGACCAGAATGGA | p.Leu466GlnfsTer6 | p.L466Qfs*6 | O00330 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| PDHX | deletion | Frame_Shift_Del | novel | c.297delN | p.Val100LeufsTer3 | p.V100Lfs*3 | O00330 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| PDHX | SNV | Missense_Mutation | novel | c.548N>T | p.Arg183Leu | p.R183L | O00330 | protein_coding | tolerated(0.07) | possibly_damaging(0.708) | TCGA-EA-A4BA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| PDHX | SNV | Missense_Mutation | c.992N>G | p.Phe331Cys | p.F331C | O00330 | protein_coding | deleterious(0.03) | possibly_damaging(0.617) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PDHX | SNV | Missense_Mutation | c.713N>T | p.Thr238Ile | p.T238I | O00330 | protein_coding | tolerated(0.07) | benign(0.047) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PDHX | SNV | Missense_Mutation | novel | c.1357N>A | p.Glu453Lys | p.E453K | O00330 | protein_coding | tolerated(0.08) | benign(0.297) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PDHX | SNV | Missense_Mutation | c.1427G>A | p.Arg476Gln | p.R476Q | O00330 | protein_coding | deleterious(0.02) | probably_damaging(0.978) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PDHX | SNV | Missense_Mutation | rs371811647 | c.1279N>A | p.Glu427Lys | p.E427K | O00330 | protein_coding | tolerated(0.07) | benign(0.206) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8050 | PDHX | KINASE | AUTOANTIGEN | 8464876 | ||
| 8050 | PDHX | KINASE | ANTIOXIDANT | 14607783 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |